Jay Olson
Stock Analyst at Oppenheimer
(3.88)
# 596
Out of 4,670 analysts
236
Total ratings
41.38%
Success rate
13.03%
Average return
Main Sectors:
Stocks Rated by Jay Olson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INO Inovio Pharmaceuticals | Maintains: Outperform | $33 → $15 | $4.07 | +268.55% | 2 | Nov 18, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Outperform | $70 → $60 | $14.30 | +319.58% | 8 | Nov 11, 2024 | |
| BIIB Biogen | Maintains: Outperform | $270 → $255 | $157.90 | +61.49% | 25 | Oct 31, 2024 | |
| TERN Terns Pharmaceuticals | Initiates: Outperform | $17 | $5.79 | +193.61% | 1 | Oct 31, 2024 | |
| SAGE Sage Therapeutics | Maintains: Perform | $9 → $8 | $5.17 | +54.74% | 8 | Oct 30, 2024 | |
| INCY Incyte | Maintains: Outperform | $81 → $82 | $71.72 | +14.33% | 14 | Oct 30, 2024 | |
| RVMD Revolution Medicines | Maintains: Outperform | $55 → $60 | $56.75 | +5.73% | 8 | Oct 28, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Outperform | $375 → $350 | $347.45 | +0.73% | 10 | Oct 23, 2024 | |
| GLTO Galecto | Maintains: Outperform | $9 → $10 | $5.62 | +77.94% | 4 | Oct 17, 2024 | |
| VKTX Viking Therapeutics | Reiterates: Outperform | $138 | $52.59 | +162.41% | 8 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $6 | $0.33 | +1,746.15% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $66 → $62 | $14.60 | +324.66% | 12 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $1.72 | +365.12% | 1 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 | $20.54 | +133.69% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $380 | $294.53 | +29.02% | 23 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $216 → $219 | $125.65 | +74.29% | 15 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 | $35.61 | -18.56% | 4 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $12 | $2.44 | +391.80% | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 | $5.66 | +218.30% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 | $2.51 | +298.41% | 5 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $95 | $47.88 | +98.41% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $19 | $16.37 | +16.07% | 14 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.12 | +506.80% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $24.55 | +103.67% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $72 → $75 | $34.01 | +120.52% | 3 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 | $0.43 | +2,004.28% | 4 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 | $22.05 | +262.81% | 4 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $25 | $2.10 | +1,090.48% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | n/a | $8.76 | - | 6 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 → $50 | $3.05 | +1,539.34% | 4 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $25 → $21 | $9.34 | +124.84% | 9 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $68 | $24.69 | +175.42% | 3 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Perform | $5 → $3 | $1.05 | +185.71% | 5 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $2.80 | - | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $84 | $16.48 | +409.71% | 1 | Mar 20, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.37 | - | 3 | Jul 11, 2017 |
Inovio Pharmaceuticals
Nov 18, 2024
Maintains: Outperform
Price Target: $33 → $15
Current: $4.07
Upside: +268.55%
Intellia Therapeutics
Nov 11, 2024
Maintains: Outperform
Price Target: $70 → $60
Current: $14.30
Upside: +319.58%
Biogen
Oct 31, 2024
Maintains: Outperform
Price Target: $270 → $255
Current: $157.90
Upside: +61.49%
Terns Pharmaceuticals
Oct 31, 2024
Initiates: Outperform
Price Target: $17
Current: $5.79
Upside: +193.61%
Sage Therapeutics
Oct 30, 2024
Maintains: Perform
Price Target: $9 → $8
Current: $5.17
Upside: +54.74%
Incyte
Oct 30, 2024
Maintains: Outperform
Price Target: $81 → $82
Current: $71.72
Upside: +14.33%
Revolution Medicines
Oct 28, 2024
Maintains: Outperform
Price Target: $55 → $60
Current: $56.75
Upside: +5.73%
Madrigal Pharmaceuticals
Oct 23, 2024
Maintains: Outperform
Price Target: $375 → $350
Current: $347.45
Upside: +0.73%
Galecto
Oct 17, 2024
Maintains: Outperform
Price Target: $9 → $10
Current: $5.62
Upside: +77.94%
Viking Therapeutics
Sep 25, 2024
Reiterates: Outperform
Price Target: $138
Current: $52.59
Upside: +162.41%
Sep 23, 2024
Upgrades: Outperform
Price Target: $6
Current: $0.33
Upside: +1,746.15%
Aug 14, 2024
Maintains: Outperform
Price Target: $66 → $62
Current: $14.60
Upside: +324.66%
Aug 14, 2024
Assumes: Outperform
Price Target: $8
Current: $1.72
Upside: +365.12%
Aug 7, 2024
Maintains: Outperform
Price Target: $48
Current: $20.54
Upside: +133.69%
Aug 7, 2024
Maintains: Outperform
Price Target: $380
Current: $294.53
Upside: +29.02%
Aug 2, 2024
Maintains: Outperform
Price Target: $216 → $219
Current: $125.65
Upside: +74.29%
Jul 30, 2024
Maintains: Outperform
Price Target: $29
Current: $35.61
Upside: -18.56%
Jun 18, 2024
Maintains: Perform
Price Target: $12
Current: $2.44
Upside: +391.80%
May 15, 2024
Maintains: Outperform
Price Target: $18
Current: $5.66
Upside: +218.30%
May 15, 2024
Maintains: Outperform
Price Target: $10
Current: $2.51
Upside: +298.41%
May 10, 2024
Maintains: Outperform
Price Target: $102 → $95
Current: $47.88
Upside: +98.41%
May 6, 2024
Maintains: Perform
Price Target: $19
Current: $16.37
Upside: +16.07%
Apr 12, 2024
Initiates: Outperform
Price Target: $25
Current: $4.12
Upside: +506.80%
Apr 11, 2024
Initiates: Outperform
Price Target: $50
Current: $24.55
Upside: +103.67%
Apr 9, 2024
Maintains: Outperform
Price Target: $72 → $75
Current: $34.01
Upside: +120.52%
Mar 27, 2024
Maintains: Outperform
Price Target: $9
Current: $0.43
Upside: +2,004.28%
Mar 7, 2024
Maintains: Outperform
Price Target: $80
Current: $22.05
Upside: +262.81%
Mar 5, 2024
Reiterates: Outperform
Price Target: $25
Current: $2.10
Upside: +1,090.48%
Mar 5, 2024
Maintains: Perform
Price Target: n/a
Current: $8.76
Upside: -
Nov 30, 2023
Maintains: Outperform
Price Target: $120 → $50
Current: $3.05
Upside: +1,539.34%
Nov 22, 2023
Maintains: Perform
Price Target: $25 → $21
Current: $9.34
Upside: +124.84%
Jun 6, 2023
Maintains: Outperform
Price Target: $70 → $68
Current: $24.69
Upside: +175.42%
Mar 6, 2023
Maintains: Perform
Price Target: $5 → $3
Current: $1.05
Upside: +185.71%
Oct 13, 2022
Downgrades: Perform
Price Target: n/a
Current: $2.80
Upside: -
Mar 20, 2018
Maintains: Outperform
Price Target: $70 → $84
Current: $16.48
Upside: +409.71%
Jul 11, 2017
Upgrades: Outperform
Price Target: n/a
Current: $1.37
Upside: -